Solfa

Quick links to important sections

Solfa

Method of action: Stomatological Preparations

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solfa

Quick Facts

Property Description
Active ingredient Amlexanox
Form Topical adherent oral paste, Tablet
Pharmacological class Anti-allergic agent, Immunomodulator
Common use Relief from inflammatory and allergic symptoms
Origin Synthetic organic compound

What is Solfa?

Solfa is the commercial designation for a pharmaceutical product containing the active drug Amlexanox, which is broadly classified as an anti-allergic agent and a general immunomodulator. Its fundamental function is to modulate immune and inflammatory responses to alleviate associated symptoms.

Amlexanox: Identity, Class, and Differentiation

The core of Solfa is Amlexanox, identified as a synthetic organic compound derived from a pyridochromene-derived monocarboxylic acid structure. This unique structure differentiates it from conventional, single-target antihistamines. Amlexanox is officially classified within therapeutic categories for both stomatological preparations and other systemic drugs for obstructive airway diseases, indicating its broad capacity to act on immune processes, whether administered locally or systemically. The mechanism involves significant interference with the chemical signals that trigger allergic and inflammatory responses.

Form, Composition, and General Purpose

The most recognized formulation of Solfa is the topical adherent oral paste, a specific dosage form that facilitates concentrated, localized application directly onto affected areas, distinguishing its delivery method from simple washes. The paste contains Amlexanox—typically at a 5% concentration—suspended in an adhesive oral paste base that helps ensure the drug remains in contact with the tissue. The general therapeutic purpose of the drug is characterized by its ability to lessen the degree of physical discomfort, swelling, and irritation that stems from an overactive immune or inflammatory process, thereby providing foundational relief in scenarios where inflammation is the root cause.

Regulatory References

  1. Amlexanox Drug Information - MedlinePlus

What side effects are possible with Solfa?

Possible side effects and safety information

The description of possible side effects and safety information for Solfa (Amlexanox oral paste) is derived strictly from official government regulatory documents.

Most documented adverse effects relate to the administration site and are classified as transient, implying a short duration. Regulatory data from clinical trials report these local reactions—which include pain, stinging, and burning at the site of application—in the 1-2% frequency range, meaning they are considered common within that study population [FDA Label].

Other adverse reactions are generally classified as infrequent (reported by less than 2% of patients) and are grouped by the affected physiological system:

  • Gastrointestinal Disorders: Infrequent reports include nausea, diarrhea, and contact mucositis (inflammation of the oral lining in contact with the paste), as well as new mouth ulceration.
  • Systemic and Nervous System Disorders: Infrequent reports include headache and sore throat.
  • Immune System Disorders: Reports of abnormal liver function tests have also been noted in official documents [HPRA/SmPC].

Solfa is formally contraindicated in individuals with a known hypersensitivity (allergy) to Amlexanox or any of the formulation's inactive components. Although rare, a serious allergic reaction is a documented risk, which can manifest as swelling of the face, tongue, or throat, or difficulty breathing.

Official labels detail specific constraints for certain populations:

Population Regulatory Safety Status
Pregnancy Classified as Category B; use only if clearly needed [FDA Label].
Lactation Caution is advised; some regulatory sources state it should not be used [HPRA/SmPC].
Pediatrics Safety and effectiveness have not been established for the oral paste formulation.
Renal/Hepatic Impairment Caution is advised due to a lack of specific studies in these patient groups [HPRA/SmPC].

Overdose and Emergency Response

Official Regulatory Information for Solfa Overdosage

The official regulatory profile for Solfa (Amlexanox) overdosage is defined by its low predicted systemic toxicity, based on extensive government assessments of the drug's topical formulation. Regulatory documents confirm the absence of formal reports of human ingestion overdosage for this product, which constrains the available clinical data on acute toxicity.

Overdose Scope and Risk Regulatory Statement
Documented Manifestations The primary potential manifestations cited following acute ingestion are limited to gastrointestinal upset, which may include diarrhea and vomiting.
Toxicity Classification Systemic exposure following the ingestion of the entire tube of oral paste is expected to remain well below the maximum nontoxic dose established in animal studies, signifying a low systemic risk.
Population Notes No specific population-based risk factors related to age or organ function are documented in the official overdose section.

Management and Emergency Response

Regulatory documents confirm that no specific antidote is known or listed for the management of an overdose of this topical formulation. Furthermore, specific procedural interventions like gastric lavage or activated charcoal are not documented as mandated measures in the official overdose section. Management, if required, relies entirely on general symptomatic and supportive care, addressed according to the observed clinical manifestations. Mandatory urgent help-seeking requirements are not explicitly tied to the ingestion overdose scenario but adhere to standard regulatory guidance for any serious adverse event.

Therapeutic Uses of Solfa

What Solfa Treats: Main Uses and Benefits

Solfa is commonly used to address symptoms related to acute or episodic changes, providing targeted relief and support for inflammatory, immune-mediated conditions within the mouth. The medication is relevant in conditions involving inflammatory or irritative processes, such as Recurrent Aphthous Ulcers (canker sores). It is applied in contexts involving heightened systemic burden caused by acute oral lesions.


Key Therapeutic Domains

Solfa is relevant when symptoms create noticeable physiological strain, such as localized discomfort. It is applied when groups of symptoms, particularly oral pain and discomfort, appear suddenly or fluctuate. The medication is relevant for easing symptoms related to slowed epithelial healing. It also supports the handling of distressing manifestations like redness and irritation. This therapeutic support contributes to easing the overall symptom load.

Quick Fact Symptomatic Support Area
Condition Focus Recurrent Aphthous Ulcers (canker sores)
Primary Symptom Target Localized oral pain and discomfort
Therapeutic Role Supports the healing process

Patient Benefit

Solfa is used in situations involving recurrent or episodic manifestations where additional symptomatic support is needed. It is considered relevant for managing symptoms that interfere with daily comfort. This supportive therapy helps improve day-to-day comfort during symptomatic periods and assists with maintaining functional stability.

Eligibility and Restrictions for Use

Who Can and Cannot Use Solfa?

Eligibility for using Solfa (Amlexanox oral paste) is strictly defined by regulatory guidelines concerning age, known allergies, immune status, and specific physiological states.

Populations for Whom Use is Restricted or Contraindicated

Solfa is contraindicated for any patient with a known hypersensitivity to the active ingredient, Amlexanox, or any other component in the paste formulation. Use is mathbfnot indicated for patients whose mathbfimmune system is abnormal or compromised, according to official labeling.

Population Group Regulatory Status
Pediatric Patients (mathbf<12 years) mathbfNot Established (Safety and effectiveness are not established)
Pregnancy mathbfNot Recommended (Use only if clearly needed)
Lactation mathbfNot Recommended (Caution should be exercised)
Hepatic or Renal Impairment Caution (No specific studies conducted)

Approved Eligibility

Use of Solfa is approved for mathbfadults and adolescents 12 years of age and older under standard labeled conditions. No specific information is available in official labeling comparing the safety or effectiveness of Solfa in older adults with that in younger patient populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Solfa (Amlexanox)

Entity/Classification Official Regulatory Documentation
Interaction Risk Classified as Low Risk of systemic interaction, based on minimal systemic absorption and in vitro data showing minor effect on CYP450 isozymes (metabolic neutrality).
Interacting Substances None listed as formally interacting. No specific combination is documented as contraindicated due to systemic risk.
Population Notes Regulatory caution is advised for patients with hepatic impairment and renal impairment because specific pharmacokinetic studies have not been conducted in these groups.
Substance Restriction Smokers were excluded from clinical trials, meaning the official data does not apply to this substance use.
Timing Rules No mandatory timing separation rules are specified based on systemic interaction risk.

Official interaction statements:

  • The potential for systemic drug-drug interactions is low due to minimal systemic absorption of the active ingredient.
  • The drug is unlikely to cause a significant effect on other medicines metabolized through the CYP450 pathway.
  • No specific interacting medicinal products are listed, and no combination is formally contraindicated due to interaction risk.
  • Caution is noted for use in patients with hepatic or renal impairment because specific pharmacokinetic data for these groups is unavailable.
  • Smokers were excluded from clinical trials, which limits the applicability of the safety and effectiveness data to this group.

Connection to the overall interaction profile

The interaction profile is characterized by the product's low potential for systemic exposure. This regulatory assessment supports the conclusion of low systemic risk, with the primary official constraints relating to a lack of pharmacokinetic data in patients with impaired clearance and the exclusion of tobacco users from the clinical study population.

Mechanism of Action

Solfa, containing Amlexanox, exerts its physiological effect through a pleiotropic (multi-target) mechanism that modulates inflammatory and allergic signaling pathways. It operates in two major, complementary mechanistic domains that converge to modulate local tissue signaling.

️ Inhibition of the Inflammatory Master Switch

The drug’s first mechanism targets the core genetic program for inflammation by inhibiting key cellular enzymes, notably IκB Kinase ϵ (⏣IKK-ϵ) and TANK-binding Kinase 1 (⏣TBK1). This action suppresses the activation of the NF-κB pathway , which is the master switch for producing pro-inflammatory proteins and cytokines. This early molecular suppression restricts the genetic signal that drives tissue inflammation.

️ Regulation of Allergic Mediator Release

The second mechanism involves the modulation of chemical messengers within immune cells. Amlexanox inhibits Phosphodiesterase 4B (⏣PDE4B), leading to increased levels of the inhibitory messenger cyclic AMP (⏣cAMP). This rise stabilizes mast cells and leukocytes, directly blocking their ability to release mediators like histamine and leukotrienes, thereby reducing specific physiological consequences such as increased vascular permeability and local neural signaling.

Dosage and Administration Information

How to Use Solfa

Solfa, containing the active drug Amlexanox, is administered through topical application and is intended for a short-term course of treatment. The administration protocol is standardized to ensure correct use and adherence to the affected oral area. This section describes the high-level usage principles.


Administration and Dosing

The approved dosage form is the 5% oral paste, and it must be applied directly to the lesion. The recommended adult dosing regimen is an application of a small amount—approximately 1/4 inch (0.5 cm to 0.6 cm)—sufficient to completely cover the ulcer.

Usage Parameter Official Instruction
Route & Form Topical 5% Oral Paste
Frequency Four times a day (Quad Daily)
Course Duration Use for up to 10 days or until the ulcer heals

Contextual Usage Principles

To maximize the intended effect, the paste should be applied to the lesion after meals and following oral hygiene. The procedure involves gently drying the ulcer area and then dabbing the paste onto the lesion with a clean fingertip; the paste is not to be rubbed in.

The treatment is an acute, duration-limited course. If a dose is missed, it should be applied as soon as the user remembers, unless it is near the time of the next scheduled application, in which case the missed dose should be skipped; a double dose must not be applied. No specific high-level dose adjustments are established for older adults or in cases of renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Solfa


Evidence for Use in Recurrent Aphthous Ulcers (RAUs)

The primary research for Solfa (Amlexanox oral paste) has focused on Recurrent Aphthous Ulcers (RAUs), often called canker sores. This evidence comes mainly from randomized controlled trials (RCTs). These are studies in which participants are randomly assigned to receive either the Solfa paste or a non-active paste, called a vehicle, allowing researchers to monitor and record any variations between the groups.

The studies were short-term and relevant in trials assessing short-term or episodic symptom patterns associated with an ulcer flare-up. Researchers monitored outcomes related to physical discomfort, specifically measuring the time until the ulcer was fully healed and tracking how patient-reported outcomes describing perceived discomfort changed over the treatment interval. Findings describe patterns observed in the studies regarding the outcomes of healing time and pain scores between the group applying Solfa and the group applying the non-active paste. This evidence was used to explore symptom patterns during the acute, or short-term, phase of the condition.


Design and Scope of Clinical Trials

The clinical trials that examined Solfa for RAUs focused on specific populations. They generally included adults and adolescents aged 12 and older who were otherwise healthy and had non-severe (minor) aphthous ulcers. Participants were often excluded if they had underlying systemic conditions that might affect their immune system, meaning the research insights are most applicable to the groups studied.

The research was designed to explore short-term symptom changes and typically monitored responses only for a defined, brief time. This means follow-up durations were limited, with the main assessments concentrated within the first week of application. The primary evidence is most concentrated on the measurements of pain and healing during the acute episode.


What is Still Uncertain About Solfa's Research

The existing research landscape highlights several areas where more data or clarity would be beneficial. The evidence quality varies across studies, particularly when looking beyond the core regulatory trials. A key limitation is the focus on minor RAUs. There is limited research for the use of Solfa in severe or major aphthous ulcers. Additionally, comparative evidence is lacking for how Solfa was studied against all other available treatments for canker sores, as the main trials used a non-active paste for comparison. Data for certain specific groups, such as children under 12 or individuals with systemic diseases, also remains limited.

Frequently Asked Questions (FAQ)

Common questions about Solfa (FAQ)


Q: Are there any common supplements or vitamins that interact with Solfa?

Official regulatory documents indicate a low potential for the active ingredient in Solfa to cause drug interactions. This is because minimal amounts of the drug are absorbed into the body. No specific common supplements or vitamins are formally listed in official labeling as interacting with Solfa.

Q: Why is Solfa prescribed for condition X when it is usually used for condition Y?

Solfa is approved in the US for the treatment of aphthous ulcers (canker sores). However, the active ingredient, Amlexanox, is broadly classified as an anti-allergic and immunomodulator. Because of this, official information shows that in some regions, it has also been approved and classified for use in treating certain allergic conditions like asthma or rhinitis.

Q: How quickly should I expect to feel a difference after starting Solfa?

Studies examined the time it took for ulcers to heal and for pain to subside. Regulatory reviews of clinical trial summaries show a difference in the complete resolution of ulcer pain compared to a non-active paste starting as early as two days. Complete healing time for the ulcer itself was noted to start differing significantly from the control group around the fourth day of treatment.

Q: How long does Solfa stay in your system after the last dose?

Solfa is absorbed into the bloodstream in very small amounts due to its topical application. According to official pharmacokinetic data, the amount that is absorbed has an elimination half-life of approximately 3.5 pm 1.1 hours in healthy people. This measurement indicates the time it takes for half of the systemically absorbed drug to be removed from the body.

Q: What is the risk of having an allergic reaction to Solfa?

Solfa is contraindicated, meaning its use is prohibited, for anyone with a known hypersensitivity to the active ingredient, Amlexanox, or any other component in the paste. Although serious allergic reactions are rare, official documents list symptoms like swelling of the face or throat, difficulty breathing, or hives, which are symptoms that should be reported to a healthcare professional right away.

Q: What does the research say about Solfa's long-term use?

The clinical trials reviewed by regulatory bodies focused exclusively on short-term use, typically for up to 10 days, to treat the acute phase of aphthous ulcers. No long-term safety or efficacy data for continuous use are available in the official labeling. The information available is concentrated on the drug’s use as a short-term, acute course of treatment.

Q: Are there any foods or drinks that should be avoided while taking Solfa?

Official labeling generally states there are no mandatory restrictions on foods, beverages, or activity when using Solfa, as systemic absorption is low. However, certain acidic drinks and irritating foods may cause local discomfort or hinder the natural healing process of the ulcer itself.

Q: Can Solfa be taken by adults over 65 years old?

Solfa is approved for use in adults and adolescents 12 years of age and older. However, regulatory documents state there is no specific information available from clinical trials comparing the drug's safety or effectiveness in older adults (over 65) with that in younger adult patient populations.

Q: Are there specific symptoms that mean I should stop taking Solfa and call a doctor?

Official patient information describes the symptoms of a serious allergic reaction that require reporting to a healthcare professional, such as swelling of the face, tongue, or throat, hives, or difficulty breathing. In addition, new mouth ulcers or a severe skin rash that develops during treatment are also documented events that typically warrant professional consultation.

Q: Does Solfa interact with common pain relievers like ibuprofen or acetaminophen?

Due to the minimal systemic absorption of Solfa's active ingredient, the potential for drug-drug interactions with common over-the-counter pain relievers, such as ibuprofen or acetaminophen, is considered low according to official regulatory assessments.

Q: How is Solfa eliminated from the body?

The small amount of Solfa that is absorbed into the body is primarily eliminated through metabolic processes called hydroxylation and conjugation. The resulting metabolic products are then mostly excreted from the body through the urine.

Q: What is the half-life of Solfa?

The elimination half-life of the active ingredient, Amlexanox, is reported in official documents to be approximately 3.5 pm 1.1 hours. The half-life describes the time required for the amount of systemically absorbed drug in the body to decrease by half.

Q: Is it safe to take Solfa if I am trying to become pregnant?

Regulatory documents classify Solfa as Pregnancy Category B, indicating that animal studies have not demonstrated a risk to the fetus. However, official information indicates that use during pregnancy is recommended only if clearly needed. Consultation with a healthcare professional is noted as necessary when considering use during pregnancy planning.

Q: Does taking Solfa with certain fruit juices cause problems?

Official labeling contains no restrictions related to beverages. However, regulatory patient information notes that acidic drinks, such as certain fruit juices, might cause irritation to existing mouth ulcers. This is a local effect and not related to a systemic drug interaction.

Q: Are there any known interactions between Solfa and alcohol?

Official drug interaction information does not list alcohol as a specific substance to avoid due to systemic interaction risk. However, alcohol is known to irritate mouth ulcers and surrounding tissues. The appropriateness of using alcohol during treatment is a topic for consultation with a healthcare professional.

Q: What is the purpose of the non-active ingredients in Solfa tablets?

The primary formulation is an oral paste. For this paste, the non-active ingredients create an 'adhesive oral paste base.' The purpose of this base is to help the medication stay fixed to the ulcerated tissue, ensuring prolonged contact with the active drug.

Q: What are the ingredients in Solfa that people are often allergic to?

Solfa is formally contraindicated for individuals with a known hypersensitivity to the active ingredient, Amlexanox, or any of the inactive ingredients used in the specific paste formulation. Official documents reference the importance of checking the full list of components when known allergies exist.

Q: Does Solfa have to be taken at the exact same time every day?

The official regimen is based on a four-times-a-day schedule. Official labeling primarily emphasizes the timing relative to meals (after meals and at bedtime) and includes instructions for skipping a dose if it is missed.

Q: Is it necessary to finish the entire course of Solfa as prescribed?

Regulatory documents state that Solfa should be used until the ulcer heals, but for a maximum duration of 10 days. If the ulcer does not show significant healing or pain reduction in 10 days, official labeling notes that professional consultation is warranted.

How should Solfa be stored and disposed of?

Storage Conditions

Solfa (Amlexanox Oral Paste) must be stored at Controlled Room Temperature, specifically at 25 C (77 F), with permitted excursions between 15 C and 30 C (59 F and 86 F). The product must be protected from heat, and it is prohibited to refrigerate or freeze the paste.

To ensure stability and integrity, the container (tube) must be kept tightly closed.

Child Safety and Disposal

Consistent with regulatory requirements, this medicine must be kept out of the reach of children. Regarding disposal, any remaining or expired product should be discarded using a drug take-back program or by following standard FDA guidelines for household disposal to prevent environmental contamination and misuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Solfa found in:

A-Z Index: